SG10202009859YA - Compositions and methods for treating cns disorders - Google Patents

Compositions and methods for treating cns disorders

Info

Publication number
SG10202009859YA
SG10202009859YA SG10202009859YA SG10202009859YA SG10202009859YA SG 10202009859Y A SG10202009859Y A SG 10202009859YA SG 10202009859Y A SG10202009859Y A SG 10202009859YA SG 10202009859Y A SG10202009859Y A SG 10202009859YA SG 10202009859Y A SG10202009859Y A SG 10202009859YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cns disorders
treating cns
treating
Prior art date
Application number
SG10202009859YA
Other languages
English (en)
Inventor
Botella Gabriel Martinez
Francesco Salituro
Albert Robichaud
Boyd Harrison
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55747445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202009859Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of SG10202009859YA publication Critical patent/SG10202009859YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG10202009859YA 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders SG10202009859YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462064961P 2014-10-16 2014-10-16

Publications (1)

Publication Number Publication Date
SG10202009859YA true SG10202009859YA (en) 2020-11-27

Family

ID=55747445

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202009859YA SG10202009859YA (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders
SG10202009861SA SG10202009861SA (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders
SG11201703073UA SG11201703073UA (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202009861SA SG10202009861SA (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders
SG11201703073UA SG11201703073UA (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders

Country Status (21)

Country Link
US (7) US10577390B2 (enrdf_load_stackoverflow)
EP (3) EP3885352B1 (enrdf_load_stackoverflow)
JP (4) JP6909155B2 (enrdf_load_stackoverflow)
KR (2) KR102612943B1 (enrdf_load_stackoverflow)
CN (7) CN117024502A (enrdf_load_stackoverflow)
AR (1) AR102306A1 (enrdf_load_stackoverflow)
AU (5) AU2015331749A1 (enrdf_load_stackoverflow)
BR (1) BR112017007902B1 (enrdf_load_stackoverflow)
CA (1) CA2964766A1 (enrdf_load_stackoverflow)
CO (1) CO2017004649A2 (enrdf_load_stackoverflow)
IL (3) IL291533B2 (enrdf_load_stackoverflow)
JO (1) JO3724B1 (enrdf_load_stackoverflow)
MX (3) MX2021004492A (enrdf_load_stackoverflow)
MY (1) MY190408A (enrdf_load_stackoverflow)
NZ (1) NZ769008A (enrdf_load_stackoverflow)
PE (1) PE20170925A1 (enrdf_load_stackoverflow)
PH (2) PH12021550427A1 (enrdf_load_stackoverflow)
RU (2) RU2733756C2 (enrdf_load_stackoverflow)
SG (3) SG10202009859YA (enrdf_load_stackoverflow)
TW (3) TWI762436B (enrdf_load_stackoverflow)
WO (1) WO2016061527A1 (enrdf_load_stackoverflow)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291654A1 (en) 2011-10-14 2015-10-15 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
PT2887944T (pt) 2012-08-21 2022-01-10 Sage Therapeutics Inc Alopregnanolona para tratamento do estado de mal epiléptico refratário
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PT2986624T (pt) 2013-04-17 2020-07-07 Sage Therapeutics Inc Esteroides neuroativos 19-nor para métodos de tratamento
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
KR20230172622A (ko) 2013-04-17 2023-12-22 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
DK3021852T3 (da) 2013-07-19 2021-03-15 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
JP6745274B2 (ja) 2015-01-26 2020-08-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
JP7049313B2 (ja) 2016-07-11 2022-04-06 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
TWI620545B (zh) * 2017-01-20 2018-04-11 長青生醫科技股份有限公司 生物參數量測方法及其裝置
RS63343B1 (sr) 2017-08-07 2022-07-29 Alkermes Inc Biciklični inhibitori histonske deacetilaze
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
IL310454A (en) * 2017-12-22 2024-03-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
MX2020006608A (es) * 2017-12-22 2020-11-06 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
WO2019154247A1 (zh) * 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 甾族类衍生物调节剂、其制备方法和应用
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
MX2021004159A (es) * 2018-10-12 2021-09-08 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.
DK3867261T3 (da) * 2018-10-19 2025-08-18 Sage Therapeutics Inc 9(11)-umættede neuroaktive steroider og deres anvendelsesmetoder
CN109369762B (zh) * 2018-10-31 2021-06-18 湖南玉新药业有限公司 17-甲酸甾族化合物的制备方法
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
MA54594A (fr) 2018-12-05 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et leurs procédés d'utilisation
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
IL283960B2 (en) * 2018-12-17 2025-09-01 Intra Cellular Therapies Inc History of deuterated 3-hydroxy-3-methoxymethyl-pergan-21-(h1-imidazol-1-yl)-20-one and pharmaceutical preparations containing them
KR20210107050A (ko) * 2018-12-21 2021-08-31 세이지 테라퓨틱스, 인크. 3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물
EP3909967A4 (en) * 2019-01-08 2022-11-09 Chengdu Kanghong Pharmaceutical Co., Ltd. STEROID COMPOUND AND USE THEREOF AND METHOD OF MANUFACTURE THEREOF
AU2020231506A1 (en) * 2019-03-04 2021-09-30 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause
EP3976628A1 (en) * 2019-05-31 2022-04-06 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
EP3990469A1 (en) * 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) * 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
EP4135710A4 (en) * 2019-09-30 2023-12-06 Eliem Therapeutics (UK) Ltd Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
CN114727989A (zh) * 2019-10-02 2022-07-08 普拉西斯精密医药公司 Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
AU2021241622A1 (en) * 2020-03-25 2022-10-20 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
EP4161530A4 (en) * 2020-06-08 2024-06-26 Eliem Therapeutics (UK) Ltd METHODS OF TREATING WOMEN'S HEALTH CONDITIONS RELATED TO SEX HORMONES
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
JP2023539125A (ja) * 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)
EP4199723A4 (en) * 2020-10-01 2024-09-04 Eliem Therapeutics (UK) Ltd METHODS OF TREATMENT OF FIBROMYALGIA WITH NEUROACTIVE STEROIDS
WO2022072621A1 (en) * 2020-10-01 2022-04-07 Eliem Therapeutics (UK) Ltd Method of treating gaba mediated disorders
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
US20220296614A1 (en) * 2021-03-19 2022-09-22 Eliem Therapeutics (UK) Ltd Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders
US20220296613A1 (en) * 2021-03-19 2022-09-22 Eliem Therapeutics (UK) Ltd Food-independent dosing of cv-10155 to treat gabaa disorders
EP4329751A4 (en) * 2021-04-26 2025-03-19 Praxis Precision Medicines, Inc. Methods of treatment with neuroactive steroids
US20250170149A1 (en) 2022-02-28 2025-05-29 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
US20250345345A1 (en) * 2022-04-26 2025-11-13 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
CN120936616A (zh) 2023-03-14 2025-11-11 库里亚西班牙公司 用于制备3α-羟基-3β-烷基类固醇的方法和中间体
CN116574150A (zh) * 2023-04-27 2023-08-11 广州楷石医药有限公司 一种二氢睾酮及其中间体的制备方法
WO2024238387A1 (en) * 2023-05-12 2024-11-21 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
US3983111A (en) * 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993005786A1 (en) 1991-09-13 1993-04-01 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
CA2100067A1 (en) 1991-11-14 1993-05-15 Stanley Poler Secondary eye growth impeding device and method
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
CA2183231A1 (en) * 1994-02-14 1995-08-17 Ravindra B. Upasani Androstanes and pregnanes for allosteric modulation of gaba receptor
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
AU3125695A (en) 1994-07-21 1996-02-22 Pharmacia & Upjohn Company Neurologically active aminosteroids
JPH10509458A (ja) 1994-11-23 1998-09-14 コセンシス・インコーポレイテッド Ｇａｂａレセプターをアロステリック調節するためのアンドロスタンおよびプレグナン系列
EP0837874B1 (en) 1995-06-06 2004-12-15 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
NZ515779A (en) * 1999-04-29 2003-11-28 Purdue Pharma Ltd 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
US6717002B2 (en) 2000-02-18 2004-04-06 Taiho Pharmaceutical Co., Ltd. Method of producing steroid derivatives
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
JP2004518637A (ja) 2000-11-03 2004-06-24 ワシントン・ユニバーシティ 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
PL378577A1 (pl) 2003-03-24 2006-05-02 Sterix Limited Pochodne estrogenu jako inhibitory sulfatazy steroidowej
WO2005000869A1 (en) 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
CN1882606A (zh) 2003-11-24 2006-12-20 默克公司 雌激素受体调节剂
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
EA013744B1 (ru) * 2005-06-09 2010-06-30 Еуро-Селтик С.А. Фармацевтические композиции на основе нейроактивного стероида и их применение
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
CA2698172C (en) 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
WO2012013816A1 (en) 2010-07-30 2012-02-02 Medexis S.A. Compounds and methods for treating neoplasia
EP2667876A2 (en) 2010-12-15 2013-12-04 Harbor BioSciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
CA2828047C (en) 2011-02-15 2020-03-10 Socpra Sciences Et Genie, S.E.C. Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2762098T3 (es) 2011-03-23 2020-05-22 Etsuro Ito Método y kit para medición de superalta sensibilidad de proteína y ácido nucleico, y nuevo sustrato enzimático
CA2843436A1 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
CN119192267A (zh) 2011-09-08 2024-12-27 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US20150291654A1 (en) 2011-10-14 2015-10-15 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
MX2014008895A (es) 2012-01-23 2014-11-25 Sage Therapeutics Inc Formulaciones de esteroides neuroactivos y metodos para tratar trastornos del cns.
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MX365059B (es) 2012-06-19 2019-05-22 Intercept Pharmaceuticals Inc Preparacion, usos y formas sólidas del ácido obeticólico.
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
PT2887944T (pt) 2012-08-21 2022-01-10 Sage Therapeutics Inc Alopregnanolona para tratamento do estado de mal epiléptico refratário
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
AU2013361485B2 (en) 2012-12-18 2018-05-17 Sage Therapeutics, Inc. Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
KR20230172622A (ko) 2013-04-17 2023-12-22 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PT2986624T (pt) 2013-04-17 2020-07-07 Sage Therapeutics Inc Esteroides neuroativos 19-nor para métodos de tratamento
DK3021852T3 (da) 2013-07-19 2021-03-15 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SI3705488T1 (sl) 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
JP6745274B2 (ja) 2015-01-26 2020-08-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
WO2017044659A1 (en) 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
CN108135838A (zh) 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
WO2017087864A1 (en) 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
JP7049313B2 (ja) 2016-07-11 2022-04-06 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
WO2019045121A1 (en) 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited TREATMENT OF CNS DISEASES
US20200281943A1 (en) 2017-09-07 2020-09-10 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019094724A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
EP3788055A4 (en) 2018-05-04 2022-03-30 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US10857163B1 (en) * 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Also Published As

Publication number Publication date
US12065463B2 (en) 2024-08-20
CN117024502A (zh) 2023-11-10
WO2016061527A1 (en) 2016-04-21
US10577390B2 (en) 2020-03-03
EP3206494A1 (en) 2017-08-23
MX2021008583A (es) 2021-08-11
AU2020202892A1 (en) 2020-05-21
JP7455098B2 (ja) 2024-03-25
RU2017116732A3 (enrdf_load_stackoverflow) 2019-02-28
JP7012119B2 (ja) 2022-02-10
AU2021218132A1 (en) 2021-09-09
IL291533A (en) 2022-05-01
US20200392177A1 (en) 2020-12-17
KR102612943B1 (ko) 2023-12-13
RU2020131091A (ru) 2020-11-23
CN112961206A (zh) 2021-06-15
US20190177358A1 (en) 2019-06-13
TW201629082A (zh) 2016-08-16
US20240368213A1 (en) 2024-11-07
MX2021004492A (es) 2022-12-05
SG11201703073UA (en) 2017-05-30
TW202426002A (zh) 2024-07-01
JP6909155B2 (ja) 2021-07-28
NZ769008A (en) 2024-03-22
AR102306A1 (es) 2017-02-15
JP7692944B2 (ja) 2025-06-16
CO2017004649A2 (es) 2017-11-10
JP2020128420A (ja) 2020-08-27
TW202235090A (zh) 2022-09-16
EP4527461A3 (en) 2025-06-25
MY190408A (en) 2022-04-21
CN107404877A (zh) 2017-11-28
US11530237B2 (en) 2022-12-20
EP3206494A4 (en) 2018-07-04
PE20170925A1 (es) 2017-07-13
BR112017007902A2 (pt) 2018-11-06
RU2017116732A (ru) 2018-11-16
MX384728B (es) 2025-03-14
IL251721B (en) 2022-04-01
CN112940066A (zh) 2021-06-11
US20220220150A1 (en) 2022-07-14
AU2020202892B2 (en) 2021-08-26
IL291533B2 (en) 2025-01-01
AU2024202959A1 (en) 2024-05-23
AU2024213161A1 (en) 2024-09-12
US20220213137A1 (en) 2022-07-07
NZ731034A (en) 2024-02-23
US11542297B2 (en) 2023-01-03
PH12021550427A1 (en) 2022-11-07
IL315006A (en) 2024-10-01
AU2021218132B2 (en) 2024-05-23
EP3885352B1 (en) 2024-11-27
CN118344423A (zh) 2024-07-16
TWI762436B (zh) 2022-05-01
RU2733756C2 (ru) 2020-10-06
BR112017007902B1 (pt) 2023-12-05
AU2015331749A1 (en) 2017-05-04
CA2964766A1 (en) 2016-04-21
CN117024501A (zh) 2023-11-10
JP2017531019A (ja) 2017-10-19
PH12017500711B1 (en) 2022-12-09
EP4527461A2 (en) 2025-03-26
PH12017500711A1 (en) 2017-10-09
US20170240589A1 (en) 2017-08-24
SG10202009861SA (en) 2020-11-27
JP2022009567A (ja) 2022-01-14
MX2017005002A (es) 2018-01-23
US20230113666A1 (en) 2023-04-13
KR20170065661A (ko) 2017-06-13
KR20230170816A (ko) 2023-12-19
CN118344424A (zh) 2024-07-16
IL291533B1 (en) 2024-09-01
TWI869654B (zh) 2025-01-11
JO3724B1 (ar) 2021-01-31
JP2023071871A (ja) 2023-05-23
EP3885352A1 (en) 2021-09-29
IL251721A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
PL3206493T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
SMT202000276T1 (it) Composizioni e metodi per trattare disturbi del snc
IL275506A (en) Preparations and methods for the treatment of central nervous system disorders
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL275562A (en) Preparations and methods for the treatment of central nervous system disorders
PT3250210T (pt) Composições e métodos para o tratamento de distúrbios do snc
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
EP3280420A4 (en) Compositions and methods for treating cns disorders
IL247699A0 (en) Preparations and methods for the treatment of kidney disorders
EP3126004A4 (en) Methods and compositions for treating inflammatory disorders
ZA201800831B (en) Compositions and methods for treating and preventing neurodegenerative disorders
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
IL250114B (en) Methods and compositions for the treatment of HIV-related diseases
IL252707B (en) Compositions and methods for treating diseases
HK1242518A1 (en) Compositions and methods for treating cns disorders